Embla Medical hf
Research Embla Medical hf (EMBLA) on Bullrun: valuation model: 43.3% undervalued, market cap DKK 11.50B, P/E 19.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEMBLA
- ExchangeCO
- CountryIceland
- SectorHealthcare
- IndustryMedical Devices
- CurrencyDKK
- Valuation signal43.3% undervalued
- Market capDKK 11.50B
- P/E19.2
- Financial periodQ2 2026
- RevenueUSD 258.57M
- Net incomeUSD 29.23M
- Free cash flowUSD 31.12M
- Gross margin63.4%
Valuation Snapshot
Bullrun's latest valuation model marks Embla Medical hf as 43.3% undervalued; latest market cap is DKK 11.50B; P/E is 19.2.
Peer valuation comparison
Latest P/E is 19.18x versus a Healthcare sector median of 24.67x (22.2% below).
Latest P/E is 19.18x versus a Iceland median of 13.36x (43.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 928.69M | USD 83.34M | n/a | 62.3% | 0.2 | USD 102.51M | USD 541.57M | USD 890.55M |
| FY2024 | USD 854.89M | USD 68.28M | n/a | 62.5% | 0.16 | USD 86.16M | USD 499.79M | USD 777.19M |
| FY2023 | USD 785.68M | USD 58.39M | n/a | 61.8% | 0.14 | USD 72.65M | n/a | n/a |
| FY2022 | USD 718.65M | USD 42.51M | n/a | 61.2% | 0.1 | USD 76.63M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-13 | DKK 11.50B | 19.2 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 DKK.
About Embla Medical hf
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Embla Medical hf overvalued or undervalued?
Bullrun's valuation model currently marks Embla Medical hf as 43.3% undervalued.
What is Embla Medical hf's market cap?
Embla Medical hf's market capitalization is DKK 11.50B.
What is Embla Medical hf's P/E ratio?
Embla Medical hf's price-to-earnings (P/E) ratio is 19.2.
What does Embla Medical hf do?
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints.